GLP-1: Research Overview of Glucose Regulation
Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.
Function of Glucagon-Like Peptide-1 in Glucose Regulation
Glucagon-like peptide-1 (GLP-1) is a 30–amino acid hormone generated in the intestinal endocrine L-cells through selective processing of proglucagon. Current evidence explores how proglucagon gene expression is regulated in both the gut and the brain, as well as the mechanisms involved in post-translational modification.
GLP-1 is secreted following food intake, triggered by specific stimuli and molecular pathways. The hormone is rapidly degraded by the enzyme dipeptidyl peptidase IV, often before leaving the gut. This suggests that some of its effects may be mediated by sensory neurons in the intestine and liver that express the GLP-1 receptor.
It is important to differentiate between measurements of the active hormone, which drives endocrine functions, and the combined levels of active hormone plus metabolites, which reflect total L-cell activity and potential neural signaling.
Primary Actions of GLP-1
The main functions of GLP-1 include:
- Enhancing insulin secretion in a glucose-dependent manner (incretin effect).
- Suppressing glucagon release, which helps control post-meal blood glucose elevations.
- Slowing gastric emptying and reducing gastrointestinal secretions, contributing to the “ileal brake” mechanism.
- Regulating appetite and reducing food intake.
Because of these diverse roles, GLP-1 and GLP-1 receptor agonists are under investigation as therapeutic strategies for type 2 diabetes. Reduced secretion of GLP-1 may contribute to obesity, while excessive secretion has been linked to postprandial reactive hypoglycemia.
GLP-1 Receptor Agonists and Incretin Signaling
A newer category of antidiabetic agents, known as incretin-based therapies, acts on GLP-1 receptors to promote insulin secretion from pancreatic β-cells in a glucose-dependent fashion, particularly under hyperglycemic conditions. These drugs also suppress glucagon secretion.
Conclusion
GLP-1 plays a crucial role in maintaining glucose homeostasis through insulin enhancement, glucagon suppression, appetite regulation, and gastrointestinal modulation.
Continued research is warranted to further clarify GLP-1 receptor signalling.
Read More: aicar
REFERENCES
